Estimating the National Disease Burden and Economic Burden of Respiratory Syncytial Virus (RSV) in Thailand Authors: Kansak Boonpattharatthiti, Chonnamet Techasaensiri, Wanatpreeya Phongsamart, Pilailuk Akkapaiboon Okada, Chanthawat Patikorn, Prabda Praphasiri, Teerapon Dhippayom, Nathorn Chaiyakunapruk Published: 2026 ABSTRACT ABSTRACTBackgroundRespiratory syncytial virus (RSV), a single‐stranded negative‐sense RNA virus, causes respiratory tract infections in children and adults, leading to hospitalization and mortality. However, the national disease burden and economic impact of RSV in Thailand remain undetermined. This study aims to estimate the national disease and economic burden of RSV infections in 2023 in Thailand.MethodsAn incidence‐based approach was employed to estimate the economic burden of RSV from a societal perspective. RSV incidences were calculated from the data obtained from six sentinel surveillance sites across Thailand. The distribution of adjusted age‐specific incidence was employed to estimate RSV cases across different age groups. A micro‐costing technique with a bottom‐up method was used to calculate direct medical costs, direct non‐medical costs, and indirect costs. The results were reported in Thai Baht (THB) and USD (34.96THB = 1 USD).ResultsAn estimated 122,631 RSV cases occurred in 2023 (186 per 100,000 person‐years), with 20,842 hospitalizations (17.0%) and 1156 premature deaths (5.5%). The total economic burden was 6.2 billion THB (177 million USD), or 0.03% of Thailand's gross domestic product (GDP). This included 1 billion THB (29 million USD) in direct medical costs, 349 million THB (9.9 million USD) in direct non‐medical costs, and 4.8 billion THB (138 million USD) in indirect costs. Productivity loss from RSV‐related premature deaths was the main cost driver, accounting for 69.35% of the total burden.ConclusionRSV infection poses a substantial economic burden in Thailand, emphasizing the urgent need for targeted interventions and public health policies to reduce its impact.Keywords: disease burden, economic burden, respiratory syncytial virus, RSV, Thailand Introduction Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections (ALRI), particularly in young children, and is increasingly recognized as a significant pathogen in adults, especially older adults [1]. RSV infection rates peak during the winter in temperate regions and during the rainy season in tropical areas [2]. Globally, an estimated 33 million RSV‐associated ALRI cases occur annually among children under 5 years of age, with 3.6 million requiring hospitalization [3]. Older adults are at greater risk of RSV infection, with those having comorbidities more likely to require hospitalization compared to healthy individuals [4]. Among adults aged 60 and older, RSV is estimated to cause approximately 4 million cases annually, resulting in an economic burden of about 6.6 billion USD in the United States [5]. Beyond infants and older adults, RSV also contributes to morbidity in other age groups; however, burden data across these intermediate age groups remain limited, underscoring the importance of comprehensive, lifespan‐wide burden estimates to inform prevention strategies. Given the substantial health and economic burden of RSV, several preventive strategies have been developed. A maternal RSV vaccine (Abrysvo) has received regulatory approval and provides transplacental antibodies protecting infants in the first months of life [6]. A long‐acting monoclonal antibody (Nirsevimab and Clesrovimab) offers direct infant protection and has demonstrated efficacy in reducing RSV‐associated ALRI hospitalizations by 89.6% [7] and 84.2% [8], respectively. For older adults, RSV vaccines have similarly received regulatory approval in multiple countries. However, as of 2023, these interventions have not yet been incorporated into Thailand's National Immunization Program. Thai‐specific disease burden and economic data are therefore urgently needed to inform national policy decisions regarding the adoption and prioritization of these interventions. In Thailand, the incidence of RSV‐associated ALRI hospitalization, as detected by active population‐based surveillance in two rural provinces between 2008 and 2011, was 85 cases per 100,000 persons per year, with the highest incidence among children under 5 years old (981 cases per 100,000 persons per year), especially infants under 1 year old (1543 cases per 100,000 persons per year) [9]. However, the incidence of RSV in community settings remains undetermined. Moreover, the economic burden of RSV has been assessed for children under 2 years old, with a median cost of 539 USD per episode. Non‐hospitalized patients incurred a cost of 167 USD, whereas hospitalized cases incurred significantly higher costs, averaging 2112 USD per hospitalization [10]. Additionally, a study from the healthcare provider's perspective found that the direct medical costs of RSV infection in outpatient settings ranged from 49 USD to 125 USD, whereas hospitalized cases ranged from 1188 USD to 6766 USD [11]. However, these studies were conducted in a single hospital between 2014 and 2021 and did not account for the incidence of RSV in the community, direct non‐medical costs, or indirect costs, and no study has comprehensively assessed the disease and economic burden of RSV at the national level across different age groups. This study aims to estimate the national burden and economic impact of RSV disease in Thailand in 2023, across age groups from < 1 year to 85 years. For burden estimation, the main analysis focuses on medically attended RSV among hospital inpatient cases (defined using the SARI case definition) and hospital outpatient cases (defined using the ILI case definition), with a scenario analysis additionally conducted to explore the potential burden of RSV among patients seeking care at pharmacies, community health centers, and private clinics. Building on these burden estimates, this study also evaluates the economic impact of RSV in Thailand, encompassing both direct medical costs and indirect costs including productivity losses. Methods Overall Description The disease and economic burden of RSV in Thailand were estimated using an incidence‐based approach from a societal perspective over 1 year (2023). The overall disease burden was estimated with a modeling approach based on RSV data collected within the Thailand surveillance system. We used a micro‐costing technique with a bottom‐up method [12], following the Health Intervention and Technology Assessment Program foundation (HITAP)'s guidelines [13]. Costs were reported in 2023 Thai Baht (THB) and U.S. Dollars (USD) (1 USD = THB 34.96) [14], and adjusted using the gross domestic product (GDP) deflator [15]. The overall framework comprised four sequential components. First, RSV surveillance and health service utilization data were collected from multiple sources, including the Thailand MOPH–US CDC sentinel surveillance system and the national Health Data Center (HDC). Second, the disease burden was estimated through a stepwise calibration approach: (i) calculating crude RSV‐positive proportions from sentinel surveillance data; (ii) applying these proportions to HDC health service utilization data to estimate site‐level RSV cases; (iii) deriving age‐specific incidence distributions by calibrating US MarketScan age weights to Thai surveillance totals; and (iv) extrapolating to national case estimates using Thai population data. For non‐hospitalized community cases, estimates were further adjusted using healthcare‐seeking behavior multipliers. Third, direct medical costs (inpatient and outpatient) and indirect costs from premature mortality were estimated using a micro‐costing bottom‐up approach. Finally, the total economic burden was calculated by multiplying age‐specific case estimates by their corresponding unit costs and summing across all age groups and cost components (Figure 1). Process diagram: estimating disease and economic burden of RSV in Thailand. Data Collection RSV data were obtained from Thailand's surveillance system, which has been operated by the Ministry of Public Health–US CDC Collaboration (MOPH‐TUC) in collaboration with the US CDC since 2010. Between January and December 2023, six surveillance sites across Thailand collected weekly samples from patients meeting WHO case definitions [16], which were tested via multiplex PCR for various viruses, including RSV. A total of 2133 influenza‐like illness (ILI) samples and 2936 severe acute respiratory infection (SARI) samples were tested for RSV. Of these, 160 ILI samples and 276 SARI samples tested positive for RSV. All virological confirmation was performed exclusively at these six hospital‐based sentinel sites; ILI specimens were obtained from their outpatient departments and SARI specimens from hospitalized inpatients, and no specimens were collected or tested in non‐sentinel settings. RSV cases with only index admissions counted, such that readmissions, transfers, or repeat presentations for the same illness episode were not double counted. Healthcare‐associated (nosocomial) RSV infections were separately distinguished from community‐acquired infections in the surveillance data. The surveillance sites include Queen Sirikit National Institute of Child Health in Bangkok, Maechan hospital in Chiang Rai, Phra Nakhon Si Ayutthaya hospital in Phra Nakhon Si Ayutthaya, Prapokklao hospital in Chanthaburi, Nakhon Phanom hospital in Nakhon Phanom, and Ko Samui hospital in Surat Thani. We specifically chose not to use data from Bangkok surveillance site only from the site‐level cases estimation step, as it primarily serves as a referral center for children and adolescents and is not a good representation of the entire Bangkok population. The five active surveillance sites collectively served a combined catchment population of 506,322 persons, representing approximately 0.77% of the Thai national population of 66,052,615. RSV Disease Burden Estimation We began by estimating the number of RSV cases at each site using the proportional multiplication approach based on health service utilization data from the Health Data Center (HDC) program under the Ministry of Public Health (Appendix 1) [17]. We then used these estimates to calculate the adjusted RSV incidence and extrapolated it to estimate the total number of RSV cases nationwide. We calculated the adjusted incidence rates of RSV infection, which comprised RSV‐associated ILI and RSV‐associated SARI, across different age groups using the age‐specific distribution of RSV incidence in hospital setting, based on the 2014 Truven Health MarketScan Commercial Claims data [18], because no equivalent Thai or regional Asian dataset provided age‐specific RSV incidence distributions with sufficient granularity across the full age spectrum and differentiated between ILI and SARI. Additionally, the age distribution of RSV incidence is largely determined by age‐related immunological factors (e.g., absence of pre‐existing immunity in young infants, declining immune function in older adults) rather than by country‐specific characteristics. Accordingly, there is no compelling epidemiological rationale to expect substantial difference in this distribution between the United States and Thailand. We adjusted these incidence rates using the estimated RSV cases provided by the MOPH–TUC, the population served by five surveillance sites from the National Statistical Office (NSO) [19], and the 2023 Thai population pyramid distribution [20]. The adjusted age‐specific distribution of RSV incidence stratified patients into the following age groups: < 1 year, 1 year, 2–4 years, 5–17 years, 18–49 years, 50–64 years, 65–74 years, 75–84 years, and ≥ 85 years (Appendix 2). We estimated the total number of RSV‐associated ILI and SARI cases across different age groups for the entire country by calculating the population size in each age group using the national population data from the National Statistical Office (NSO) [19, 21], and distributing it according to the 2023 Thai population pyramid [20]. We then multiplied the population size in each age group by the adjusted age‐specific distribution of RSV‐associated ILI and SARI incidence to determine the total number of cases across age groups in each category (Appendix 3). Finally, the total number of RSV cases was the sum of all cases across different age groups. Moreover, we estimated premature deaths (defined as deaths occurring before the average Thai life expectancy of 75.3 years) associated with RSV based on the age‐specific case‐fatality ratio among 5919 hospitalized RSV‐associated SARI patients in a tertiary teaching hospital, which provided specific ratios for different age groups [11] and the case‐fatality ratio for hospitalized adults with RSV, which was derived from the national hospital databases [22] (Appendix 4). These estimated cases will serve as the base‐case analysis for calculating the total economic burden. Healthcare‐Seeking Behavior for ILI Patients We estimated the RSV disease burden beyond hospitals based on healthcare‐seeking behavior to provide a more comprehensive view of the national disease burden. Given potential differences in healthcare‐seeking behavior, we estimated RSV‐associated ILI and SARI cases separately for Bangkok [23] and other provinces [24]. For Bangkok, we first calculated the population size in each age group using the 2023 Bangkok population data from the NSO, distributing it according to the 2023 Bangkok population pyramid [25]. We then estimated the total number of RSV‐associated ILI and SARI cases by multiplying the age‐specific population size by the adjusted age‐specific incidence for each category (Appendix 5). For other provinces, we determined the total number of RSV‐associated ILI and SARI cases by subtracting the estimated RSV‐associated ILI and SARI cases for Bangkok from the total RSV‐associated ILI and SARI cases for the entire country (Appendix 6). To estimate cases in non‐hospital settings, we applied proportional healthcare‐seeking behavior specific to Bangkok [23] and other provinces [24] to the estimated number of ILI cases seeking care at public hospitals. We assumed that all patients in non‐Bangkok have the same pattern of health care seeking behavior. This estimate accounted for care received in public hospitals, private hospitals, pharmacies, community health centers, and private clinics to determine the number of ILI cases in other settings (Appendix 7). Because laboratory confirmation was available only at the hospital‐based sentinel sites, RSV cases in non‐hospital settings were not laboratory‐confirmed but were imputed by applying the age‐specific RSV‐positive proportions observed in hospital ILI surveillance to the ILI cases distributed across these settings, thereby assuming a comparable RSV‐positive fraction among ILI patients regardless of where they sought care. Accordingly, these estimates reflect medically attended, symptomatic RSV‐associated ILI and SARI, together with an estimated component for symptomatic patients who did not seek care, rather than all RSV infections; asymptomatic and untested infections were not captured. Cost Estimation From a societal perspective, costs include direct medical costs (DMC), direct non‐medical costs, and indirect costs. DMC varies depending on the healthcare setting and patient age. DMC for RSV‐associated ILI patients who seek hospital outpatient care and RSV‐associated SARI patients was based on a recently published study of 2122 RSV‐positive patients in a tertiary teaching hospital in Bangkok [11]. For patients seeking care from pharmacies, DMC was based on estimates from a previous study for treating common illness symptoms [26]. The DMC included drug costs, which were collected from four drug stores across Thailand, whereas pharmacy service costs covered basic consultations and medication dispensing [26]. DMC for patients visiting community health centers was obtained from the HITAP [27]. Similarly, the DMC for patients seeking care at private clinics was retrieved from a previous study, which estimated costs through a structured household survey of ILI patients [24], whereas the costs for private hospitals were sourced from the Department of Internal Trade [28]. Direct non‐medical costs, including transportation and food expenses for patients seeking care from hospitals, community health centers, and private clinics, were based on cost estimates from HITAP [27], whereas for pharmacy was based on a recent study in drug store [26]. Informal care costs for caregivers of patients with RSV‐associated ILI for all age groups, except those aged 18–64 years, were calculated by multiplying the number of workdays lost by caregivers (3.3 days) by the Gross National Income (GNI) per capita (668 THB per day) [29]. Similarly, informal care costs for caregivers of patients with RSV‐associated SARI were calculated based on the workdays lost (determined by the average hospitalization length from a previous study [11] across different age groups: 9 days for 0–2 years, 7 days for 2–5 years, 11 days for 5–18 years, and 20 days for 65+ years), multiplied by the GNI per capita. We assumed that one patient required one caregiver per episode. Indirect costs were calculated using the human capital approach [13]. The cost of productivity loss due to RSV was calculated separately for ILI and SARI. The productivity loss for SARI patients was calculated by multiplying the average length of hospitalization [11] by the daily GNI per capita for 2023, whereas the productivity loss for ILI patients was calculated by multiplying the number of missed workdays (4.5 days) [30] by the daily GNI per capita for 2023. The costs were calculated separately by age group. We then calculated the cost of premature deaths by multiplying the number of cases by the annual productivity from the year a patient dies until the end of the average life expectancy of the Thai population (75.3 years old) [31]. This represents an estimate of the productivity lost due to premature deaths [13]. The calculation of premature death cost can be found in Appendix 8. To estimate the economic burden of RSV‐associated ILI across the different healthcare settings, we multiplied the estimated number of ILI cases seeking care in each setting (public hospital, private hospital, pharmacy, community health center, and private clinic) by the corresponding setting‐ and age‐specific cost per case (comprising direct medical, direct non‐medical, and indirect costs), and then summed these costs across all settings to obtain the total economic burden. ILI cases that did not seek care were assigned indirect costs only. Analyses The base‐case analysis considered the total sum of DMCs, direct non‐medical costs, and indirect costs for patients who sought care at public hospitals, using a societal perspective. Scenario analysis extended this estimation to patients seeking care in other healthcare settings based on healthcare‐seeking behavior. To assess the robustness of findings and the impact of uncertainty on input parameters, a probabilistic sensitivity analysis (PSA) was conducted using Monte Carlo simulation with 10,000 iterations in Microsoft Excel. Probability distributions were assigned to each input parameter according to its statistical nature (Table 1). A gamma distribution was applied to all cost parameters, as costs are continuous, non‐negative, and typically right‐skewed. A beta distribution was applied to proportions bounded between 0 and 1, namely the health‐seeking behavior parameters and the case‐fatality ratios. A normal distribution was applied to the age‐specific incidence rates, which were derived from large‐sample surveillance estimates for which a normal approximation is appropriate. The estimated economic burden was presented as a mean with a 95% credible interval based on PSA results. Furthermore, the total economic burden of RSV will be compared with the national GDP for 2023, which was estimated at 17,922,038 million Baht [32]. TABLE 1Input parameters.ParametersBase‐case value (range)DistributionsReferencesSurveillance dataThe number of outpatient visits2,277,296Fixed—The number of ILI patients8441Fixed—The number of ILI samples tested2133Fixed—The number of ILI samples tested positive for RSV160Fixed—The number of hospitalized patients159,455Fixed—The number of SARI patients5919Fixed—The number of SARI samples tested2936Fixed—The number of SARI samples tested positive for RSV276Fixed—HDC dataThe number of outpatients from Maechan Hospital66,086Fixed[17]The number of outpatients from Phra Nakhon Si Ayutthaya Hospital152,207Fixed[17]The number of outpatients from Prapokklao Hospital159,986Fixed[17]The number of outpatients from Nakhon Phanom Hospital95,147Fixed[17]The number of outpatients from Ko Samui Hospital61,959Fixed[17]The number of outpatients from the Queen Sirikit National Institute of Child Health serves33,771Fixed[17]Total number of outpatients across all sites569,156Fixed[17]The number of outpatient visits from Maechan Hospital309,527Fixed[17]The number of outpatient visits from Phra Nakhon Si Ayutthaya Hospital598,459Fixed[17]The number of outpatient visits from Prapokklao Hospital789,401Fixed[17]The number of outpatient visits from Nakhon Phanom Hospital359,091Fixed[17]The number of outpatient visits from Ko Samui Hospital236,262Fixed[17]The number of outpatient visits from the Queen Sirikit National Institute of Child Health serves115,274Fixed[17]Total number of outpatient visits across all sites2,408,014Fixed[17]The number of hospitalized patients from Maechan Hospital14,761Fixed[17]The number of hospitalized patients from Phra Nakhon Si Ayutthaya Hospital33,501Fixed[17]The number of hospitalized patients from Prapokklao Hospital53,033Fixed[17]The number of hospitalized patients from Nakhon Phanom Hospital24,609Fixed[17]The number of hospitalized patients from Ko Samui Hospital12,240Fixed[17]The number of hospitalized patients from the Queen Sirikit National Institute of Child Health serves8219Fixed[17]Total number of hospitalized patients from all sites146,363Fixed[17]National Statistical Office (NSO) dataNumber of populations of an area that Maechan Hospital serves108,454Fixed[19, 21]Number of populations of an area that Phra Nakhon Si Ayutthaya Hospital serves142,441Fixed[19, 21]Number of populations of an area that Prapokklao Hospital serves134,271Fixed[19, 21]Number of populations of an area that Nakhon Phanom Hospital serves157,012Fixed[19, 21]Number of populations of an area that Ko Samui Hospital serves61,652Fixed[19, 21]Number of populations for the North region11,940,324Fixed[19, 21]Number of populations for the Central region12,204,885Fixed[19, 21]Number of populations for the East region5,205,868Fixed[19, 21]Number of populations for the Northeast region21,716,975Fixed[19, 21]Number of populations for the South region9,512,975Fixed[19, 21]Number of populations for the Bangkok5,471,588Fixed[19, 21]The health‐seeking behavior of ILI patients in non‐Bangkok provinces (%)Patients who seek care from public hospitals18.75 (6.59–43.01)Beta[24]Patients who seek care from community health centers37.5 (18.48–61.36)Beta[24]Patients who seek care from private clinics12.5 (3.5–36.02)Beta[24]Patients who seek care from pharmacies18.75 (6.59–43.01)Beta[24]Patients who do not seek care12.5 (3.5–36.02)Beta[24]The health‐seeking behavior of ILI patients in Bangkok (%)Patients who seek care from public hospitals23.81 (10.63–45.09)Beta[23]Patients who seek care from private hospitals9.52 (2.65–28.91)Beta[23]Patients who seek care from pharmacies47.62 (28.34–67.63)Beta[23]Patients who do not seek care19.05 (7.67–40)Beta[23]Adjusted age‐specific incidence of RSV infection across different age groups [Rate/1000 person‐years (95% CI)]Incidence of RSV in < 1 year47.29 (46.84–47.59)Normal[18, 20]Incidence of RSV in 1 year−< 2 year25.01 (24.83–25.05)Normal[18, 20]Incidence of RSV in 2–4 years8.34 (8.3–8.35)Normal[18, 20]Incidence of RSV in 5–17 years0.82 (0.77–0.8)Normal[18, 20]Incidence of RSV in 18–49 years0.41 (0.4–0.42)Normal[18, 20]Incidence of RSV in 50–64 years0.89 (0.9–0.94)Normal[18, 20]Incidence of RSV in 65–74 years1.98 (2.01–2.02)Normal[18, 20]Incidence of RSV in 75–84 years3.69 (3.62–3.68)Normal[18, 20]Incidence of RSV in ≥ 85 years5.54 (5.5–5.62)Normal[18, 20]Adjusted age‐specific incidence of RSV‐associated ILI across different age groups [Rate/1000 person‐years (95% CI)]Incidence of RSV in < 1 year36.74 (36.39–36.98)Normal[18, 20]Incidence of RSV in 1 year–< 2 year20.11 (19.96–20.14)Normal[18, 20]Incidence of RSV in 2–4 years6.7 (6.66–6.71)Normal[18, 20]Incidence of RSV in 5–17 years0.74 (0.69–0.72)Normal[18, 20]Incidence of RSV in 18–49 years0.36 (0.35–0.37)Normal[18, 20]Incidence of RSV in 50–64 years0.81 (0.82–0.85)Normal[18, 20]Incidence of RSV in 65–74 years1.69 (1.72–1.73)Normal[18, 20]Incidence of RSV in 75–84 years3.04 (2.98–3.03)Normal[18, 20]Incidence of RSV in ≥ 85 years4.63 (4.59–4.69)Normal[18, 20]Adjusted age‐specific incidence of RSV‐associated SARI across different age groups [Rate/1000 person‐years (95% CI)]Incidence of RSV in < 1 year10.55 (10.45–10.61)Normal[18, 20]Incidence of RSV in 1 year–< 2 year4.9 (4.87–4.91)Normal[18, 20]Incidence of RSV in 2–4 years1.64 (1.64–1.64)Normal[18, 20]Incidence of RSV in 5–17 years0.08 (0.08–0.08)Normal[18, 20]Incidence of RSV in 18–49 years0.05 (0.05–0.05)Normal[18, 20]Incidence of RSV in 50–64 years0.08 (0.08–0.09)Normal[18, 20]Incidence of RSV in 65–74 years0.29 (0.29–0.29)Normal[18, 20]Incidence of RSV in 75–84 years0.65 (0.64–0.65)Normal[18, 20]Incidence of RSV in ≥ 85 years0.91 (0.91–0.93)Normal[18, 20]Case‐fatality ratio (CFR) (%)CFR among hospitalized RSV patients aged 0–2 years2.47 (1.6–3.78)Beta[11]CFR among hospitalized RSV patients aged 2–5 years2.16 (0.93–4.97)Beta[11]CFR among hospitalized RSV patients aged 5–18 years17.14 (8.1–32.68)Beta[11]CFR among hospitalized RSV patients aged 18–59 years5.59 (3.65–8.15)Beta[22]CFR among hospitalized RSV patients aged 60–74 years9.66 (7.38–12.35)Beta[22]CFR among hospitalized RSV patients aged ≥ 7512.50 (9.89–15.50)Beta[22]Direct medical cost a Outpatient costs for ILI patients aged 0–2 years2153.15 (1460.59–3450.22)Gamma[11]Outpatient costs for ILI patients aged 2–5 years2149.18 (1508.71−3094.02)Gamma[11]Outpatient costs for ILI patients aged 5–18 years2744.09 (1644.4−6370.9)Gamma[11]Outpatient costs for ILI patients aged 18–65 years6650.13 (3135.65−21,635.77)Gamma[11]Outpatient costs for ILI patients aged 65+ years6150.97 (3938.45−15,745.29)Gamma[11]Inpatient costs for SARI patients aged 0–2 years19,881.43 (7821.33−32,649.17)Gamma[11]Inpatient costs for SARI patients aged 2–5 years15,430.03 (7046.02−25,258.28)Gamma[11]Inpatient costs for SARI patients aged 5–18 years28,955.65 (11,034.49−56,999.72)Gamma[11]Inpatient costs for SARI patients aged 18–65 years43,638.98 (7838.87−113,491.3)Gamma[11]Inpatient costs for SARI patients aged 65+ years50,569.29 (13,926.13–128,238.9)Gamma[11]Pharmacy care costs197.97 (79.69–316.26)Gamma[26]Private clinic care costs230.92 (−)Gamma[24]Private hospital care costs1250 (200–2300)Gamma[28]Community health center care costs126.62 (37.61–215.63)Gamma[27]Direct nonmedical cost a Transportation costs for hospital outpatients (both public and private hospitals)181.34 (152.42–210.26)Gamma[27]Food costs for hospital outpatients (both public and private hospitals)66.8 (53.46–80.14)Gamma[27]Transportation costs for community health centers68.34 (59.54–77.14)Gamma[27]Food costs for community health centers17 (12.49–21.51)Gamma[27]Transportation and food costs for patients seeking care at pharmacies and private clinics138.92 (−)Gamma[26]Informal care costs for caregivers of ILI patients (all ages except 18–65)2203.92 (0–6678.54)Gamma[11, 29]Informal care costs for caregivers of SARI patients (0–2 years)6010.68 (2671.41−6010.68)Gamma[11, 29]Informal care costs for caregivers of SARI patients (2–5 years)4674.98 (2003.56−4007.12)Gamma[11, 29]Informal care costs for caregivers of SARI patients (5–18 years)7346.39 (2003.56−8014.24)Gamma[11, 29]Informal care costs for caregivers of SARI patients (65+ years)13,357.07 (4007.12−12,689.21)Gamma[11, 29]Indirect cost a Productive loss for ILI patients (all ages)3005.34 (0–6678.54)Gamma[29, 30]Productive loss for SARI patients aged 0–2 years6010.68 (2671.41−6010.68)Gamma[11, 29]Productive loss for SARI patients aged 2–5 years4674.98 (2003.56−4007.12)Gamma[11, 29]Productive loss for SARI patients aged 5–18 years7346.39 (2003.56−8014.24)Gamma[11, 29]Productive loss for SARI patients aged 18–65 years13,357.07 (3339.27−11,353.51)Gamma[11, 29]Productive loss for SARI patients aged 65+ years13,357.07 (4007.12−12,689.21)Gamma[13]Premature death cost for SARI patients aged 0–2 years7,240,866.92 (−)Gamma[13]Premature death cost for SARI patients aged 2–5 years7,158,397.72 (−)Gamma[13]Premature death cost for SARI patients aged 5–18 years6,900,390.73 (−)Gamma[13]Premature death cost for SARI patients aged 18–65 years5,151,768.52 (−)Gamma[13]Premature death cost for SARI patients aged 65+ years1,326,041.68 (−)Gamma[13] a All costs are presented in 2023 Thai Baht. Input parameters. All costs are presented in 2023 Thai Baht. Ethics Statement This study utilized previously published, publicly available, and aggregated data sources and did not involve primary data collection, human subjects, or identifiable patient information. Accordingly, formal ethics committee/IRB review was not required. Results Incidence of RSV in Thailand Across all age groups, there were a total of 122,631 RSV estimates cases, comprising 101,789 RSV‐associated ILI cases (83.0%), and 20,842 RSV‐associated SARI cases (17.0%). Among the SARI cases, there were 1156 premature deaths (5.5%). Infants under 1 year exhibit the highest rates, with 4729 per 100,000 person‐years for RSV infection, 3674 for ILI, and 1055 for SARI. The incidence rates decline with increasing age, reaching their lowest levels in adults aged 18–49 years (41 for RSV infection, 36 for ILI, and 5 for SARI per 100,000 person‐years, respectively). The cumulative incidence across different age groups can be found in Table 2. The incidence presented in Table 2 represents cumulative RSV‐associated medically attended incidence, combining both ILI and SARI cases across outpatient and inpatient settings; it therefore reflects medically attended RSV rather than all RSV infections. TABLE 2Estimated number of patients and cumulative incidence of RSV infection, RSV‐associated ILI, and RSV‐associated SARI by age group.Age groupsNo. of RSV casesNo. of RSV‐associated ILI (%) a No. of RSV‐associated SARI (%) a No. of premature death among RSV‐associated SARICumulative incidence of RSV infection per 100,000 person‐years (95% Crl)Cumulative incidence of RSV‐associated ILI per 100,000 person‐years (95% Crl)Cumulative incidence of RSV‐associated SARI per 100,000 person‐years (95% Crl)< 1 year29,44522,879 (77.7)6566 (22.3)162 4729 (4677–4782) 3674 (3628–3721) 1055 (1029–1080) 1 year to < 2 year15,57312,520 (80.4)3052 (19.6)75 2501 (2463–2540) 2011 (1976–2046) 490 (473–508) 2–4 years15,57912,510 (80.3)3069 (19.7)66 834 (821–847) 670 (658–682) 164 (159–170) 5–17 years91198180 (89.7)939 (10.3)161 82 (80–84) 74 (72–75) 8 (8–9) 18–49 years11,1219764 (87.8)1357 (12.2)76 41 (40–42) 36 (35–37) 5 (5–5) 50–64 years12,72311,552 (90.8)1171 (9.2)81 89 (87–91) 81 (79–82) 8 (8–9) 65–74 years12,57010,747 (85.5)1823 (14.5)176 198 (195–201) 169 (166–173) 29 (27–30) 75–84 years11,8439747 (82.3)2096 (17.7)262 369 (362–376) 304 (298–310) 65 (63–68) ≥ 85 years46593890 (83.5)769 (16.5)96 554 (538–570) 463 (448–477) 91 (85–98) Total122,631101,789 (83.0)20,842 (17.0)1156 186 (185–187) 154 (153–155) 32 (31–32) a Percentages were calculated from estimated total RSV cases in each age group. Estimated number of patients and cumulative incidence of RSV infection, RSV‐associated ILI, and RSV‐associated SARI by age group. 4729 (4677–4782) 3674 (3628–3721) 1055 (1029–1080) 2501 (2463–2540) 2011 (1976–2046) 490 (473–508) 834 (821–847) 670 (658–682) 164 (159–170) 82 (80–84) 74 (72–75) 8 (8–9) 41 (40–42) 36 (35–37) 5 (5–5) 89 (87–91) 81 (79–82) 8 (8–9) 198 (195–201) 169 (166–173) 29 (27–30) 369 (362–376) 304 (298–310) 65 (63–68) 554 (538–570) 463 (448–477) 91 (85–98) 186 (185–187) 154 (153–155) 32 (31–32) Percentages were calculated from estimated total RSV cases in each age group. Total Economic Burden The total economic burden of RSV infections was estimated at 6.2 billion THB (177 million USD), with a 95% credible interval of 3.3 billion–12.3 billion THB (93 million–351 million USD). Compared to the national GDP for 2023, the economic burden of RSV is projected to constitute 0.03% of Thailand's GDP. The DMCs of RSV infections were estimated at 1 billion THB (29 million USD), with a 95% credible interval of 360 million–2.8 billion THB (10 million–80 million USD), whereas direct non‐medical costs were projected at 349 million THB (9.9 million USD), with a credible interval of 120 million–1.3 billion THB (3.4 million–36.5 million USD). Indirect costs accounted for the majority of the total economic burden, amounting to 4.8 billion THB (138 million USD), with a 95% credible interval of 2.8 billion–8.2 billion THB (79 million–235 million USD) (Table 3). This was mainly driven by the costs associated with premature deaths from RSV‐associated SARI, which contributed 4.3 billion THB (124 million USD), whereas productivity loss accounted for 481 million THB (13.8 million USD) (Appendix 9). TABLE 3Total economic burden of confirmed RSV infection.Direct medical costsDirect non‐medical costsIndirect costsTotal costsRSV‐associated ILI 417,296,476 (137,352,012–1,223,682,100) 202,612,970 (25,972,592–1,074,330,730) 305,912,361 (7,731,169–1,284,553,166) 925,821,806 (171,055,773–3,582,565,995) RSV‐associated SARI 613,116,373 (223,625,983–1,575,038,430) 146,845,216 (94,456,888–203,019,691) 4,524,188,775 (2,784,436,688–6,944,377,784) 5,284,150,365 (3,102,519,559–8,722,435,905) Gross total 1,030,412,849 (360,977,996–2,798,720,529) 349,458,186 (120,429,480–1,277,350,421) 4,830,101,136 (2,792,167,857–8,228,930,950) 6,209,972,172 (3,273,575,332–12,305,001,900) Note: Values are expressed in Thai Baht (mean with 95% Crl). Total economic burden of confirmed RSV infection. 417,296,476 (137,352,012–1,223,682,100) 202,612,970 (25,972,592–1,074,330,730) 305,912,361 (7,731,169–1,284,553,166) 925,821,806 (171,055,773–3,582,565,995) 613,116,373 (223,625,983–1,575,038,430) 146,845,216 (94,456,888–203,019,691) 4,524,188,775 (2,784,436,688–6,944,377,784) 5,284,150,365 (3,102,519,559–8,722,435,905) 1,030,412,849 (360,977,996–2,798,720,529) 349,458,186 (120,429,480–1,277,350,421) 4,830,101,136 (2,792,167,857–8,228,930,950) 6,209,972,172 (3,273,575,332–12,305,001,900) Note: Values are expressed in Thai Baht (mean with 95% Crl). Economic Burden of Confirmed RSV Infection Across Different Age Groups The economic burden of RSV infection varied across age group, with gross total costs ranging from 104 million THB (3 million USD) in the ≥ 85 years age group to 1.5 billion THB (44 million USD) in the < 1 year age group. The highest DMCs found in < 1 year age groups, with a total cost of 179 million THB (5 million USD), whereas the 75–84‐ and 65–74‐years age groups had direct medical costs of 165 and 158 million THB (4.7 and 4.5 million USD), respectively. RSV‐associated ILI has a lower economic burden than RSV‐associated SARI across all age groups. The estimated economic burden of confirmed RSV infection for other age groups is presented in Table 4. TABLE 4Economic burden of confirmed RSV infection across different age groups.Direct medical costsDirect non‐medical costsIndirect costsTotal costs< 1 yearsRSV‐associated ILI 49,261,790 (18,847,856–108,263,138) 56,100,391 (5,925,364–305,535,138) 68,759,121 (1,733,128–289,798,932) 174,121,302 (26,506,348–703,597,208) RSV‐associated SARI 130,547,383 (30,176,725–327,461,097) 41,097,229 (22,865,740–65,815,493) 1,213,846,356 (412,293,726–2,518,112,840) 1,385,490,968 (465,336,191–2,911,389,430) Gross total 179,809,173 (49,024,581–435,724,235) 97,197,620 (28,791,104–371,350,631) 1,282,605,477 (414,026,854–2,807,911,772) 1,559,612,270 (491,842,539–3,614,986,638) 1 yearsRSV‐associated ILI 26,958,120 (10,411,637–59,215,458) 30,700,489 (3,234,238–166,150,369) 37,627,878 (953,127–157,456,630) 95,286,487 (14,599,002–382,822,457) RSV‐associated SARI 60,682,541 (13,984,064–151,828,215) 19,103,288 (10,707,547–30,491,808) 564,234,068 (226,710,545–1188,922,676) 644,019,897 (251,402,156–1,371,242,699) Gross total 87,640,661 (24,395,701–211,043,673) 49,803,777 (13,941,785–196,642,177) 601,861,946 (227,663,672–1,346,379,306) 739,306,384 (266,001,158–1,754,065,156) 2–4 yearsRSV‐associated ILI 26,885,698 (11,541,116–49,590,671) 30,674,564 (3,233,301–166,118,097) 37,596,103 (952,205–157,321,609) 95,156,365 (15,726,622–373,030,377) RSV‐associated SARI 47,355,091 (8,575,406–115,551,014) 15,109,119 (9,990,744–21,755,669) 488,883,939 (39,650,220–1,808,718,611) 551,348,149 (58,216,370–1,946,025,294) Gross total 74,240,789 (20,116,522–165,141,685) 45,783,683 (13,224,045–187,873,766) 526,480,042 (40,602,425–1,966,040,220) 646,504,514 (73,942,992–2,319,055,671) 5–17 yearsRSV‐associated ILI 22,445,328 (1,628,611–89,270,546) 20,056,645 (2,106,882–108,859,519) 24,582,312 (620,044–103,393,398) 67,084,285 (4,355,537–301,523,463) RSV‐associated SARI 27,196,136 (2,819,502–95,022,846) 7,133,033 (2,985,213–13,886,681) 1,117,757,585 (135,152,654–3,090,297,040) 1,152,086,754 (140,957,369–3,199,206,567) Gross total 49,641,464 (4,448,113–184,293,392) 27,189,678 (5,092,095–122,746,200) 1,142,339,897 (135,772,698–3,193,690,438) 1,219,171,039 (145,312,906–3,500,730,030) 18–49 yearsRSV‐associated ILI 64,933,829 (230,230–443,199,567) 2,422,849 (1,913,953–3,163,977) 29,345,060 (748,428–122,473,626) 96,701,738 (2,892,611–568,837,170) RSV‐associated SARI 59,208,118 (1,495,230–292,758,796) 336,660 (261,069–450,823) 408,850,781 (182,277,670–784,700,391) 468,395,559 (184,033,969–1,077,910,010) Gross total 124,141,947 (1,725,460–735,958,363) 2,759,509 (2,175,022–3,614,800) 438,195,841 (183,026,098–907,174,017) 565,097,297 (186,926,580–1,646,747,180) 50–64 yearsRSV‐associated ILI 76,824,603 (270,812–535,645,493) 2,866,524 (2,244,369–3,745,141) 34,718,769 (874,114–146,916,188) 114,409,896 (3,389,295–686,306,822) RSV‐associated SARI 51,079,570 (1,304,262–259,015,572) 290,441 (231,959–377,644) 434,529,797 (203,394,956–769,035,553) 485,899,808 (204,931,177–1,028,428,769) Gross total 127,904,173 (1,575,074–794,661,065) 3,156,965 (2,476,328–4,122,785) 469,248,566 (204,269,070–915,951,741) 600,309,704 (208,320,472–1,714,735,591) 65–74 yearsRSV‐associated ILI 66,106,756 (5,049,619–257,791,170) 26,353,082 (2,772,695–142,331,647) 32,299,504 (818,254–135,243,017) 124,759,342 (8,640,568–535,365,834) RSV‐associated SARI 92,170,296 (1,851,184–499,751,392) 24,797,566 (12,682,995–44,310,416) 257,819,252 (161,389,949–386,916,117) 374,787,114 (175,924,128–930,977,925) Gross total 158,277,052 (6,900,803–757,542,562) 51,150,648 (15,455,690–186,642,063) 290,118,756 (162,208,203–522,159,134) 499,546,456 (184,564,696–1,466,343,759) 75–84 yearsRSV‐associated ILI 59,953,488 (4,571,395–234,173,487) 23,900,117 (2,495,003–129,099,485) 29,293,041 (738,199–123,012,657) 113,146,646 (7,804,597–486,285,629) RSV‐associated SARI 106,006,168 (2,123,242–578,441,508) 28,519,979 (14,590,286–50,751,625) 27,999,828 (14,338,511–49,482,251) 162,525,975 (31,052,039–678,675,384) Gross total 165,959,656 (6,694,637–812,614,995) 52,420,096 (17,085,289–179,851,110) 57,292,869 (15,076,710–172,494,908) 275,672,621 (38,856,636–1,164,961,013) ≥ 85 yearsRSV‐associated ILI 23,926,864 (1,829,213–93,543,978) 9,538,308 (1,009,249–51,469,988) 11,690,573 (293,670–48,937,108) 45,155,745 (3,132,132–193,951,074) RSV‐associated SARI 38,871,071 (784,162–211,014,366) 10,457,902 (5,341,398–18,682,562) 10,267,170 (5,278,930–18,143,636) 59,596,143 (11,404,490–247,840,564) Gross total 62,797,935 (2,613,375–304,558,344) 19,996,210 (6,350,647–70,152,550) 21,957,743 (5,572,600–67,080,744) 104,751,888 (14,536,622–441,791,638) Note: Values are expressed in Thai Baht (mean with 95% Crl). Economic burden of confirmed RSV infection across different age groups. 49,261,790 (18,847,856–108,263,138) 56,100,391 (5,925,364–305,535,138) 68,759,121 (1,733,128–289,798,932) 174,121,302 (26,506,348–703,597,208) 130,547,383 (30,176,725–327,461,097) 41,097,229 (22,865,740–65,815,493) 1,213,846,356 (412,293,726–2,518,112,840) 1,385,490,968 (465,336,191–2,911,389,430) 179,809,173 (49,024,581–435,724,235) 97,197,620 (28,791,104–371,350,631) 1,282,605,477 (414,026,854–2,807,911,772) 1,559,612,270 (491,842,539–3,614,986,638) 26,958,120 (10,411,637–59,215,458) 30,700,489 (3,234,238–166,150,369) 37,627,878 (953,127–157,456,630) 95,286,487 (14,599,002–382,822,457) 60,682,541 (13,984,064–151,828,215) 19,103,288 (10,707,547–30,491,808) 564,234,068 (226,710,545–1188,922,676) 644,019,897 (251,402,156–1,371,242,699) 87,640,661 (24,395,701–211,043,673) 49,803,777 (13,941,785–196,642,177) 601,861,946 (227,663,672–1,346,379,306) 739,306,384 (266,001,158–1,754,065,156) 26,885,698 (11,541,116–49,590,671) 30,674,564 (3,233,301–166,118,097) 37,596,103 (952,205–157,321,609) 95,156,365 (15,726,622–373,030,377) 47,355,091 (8,575,406–115,551,014) 15,109,119 (9,990,744–21,755,669) 488,883,939 (39,650,220–1,808,718,611) 551,348,149 (58,216,370–1,946,025,294) 74,240,789 (20,116,522–165,141,685) 45,783,683 (13,224,045–187,873,766) 526,480,042 (40,602,425–1,966,040,220) 646,504,514 (73,942,992–2,319,055,671) 22,445,328 (1,628,611–89,270,546) 20,056,645 (2,106,882–108,859,519) 24,582,312 (620,044–103,393,398) 67,084,285 (4,355,537–301,523,463) 27,196,136 (2,819,502–95,022,846) 7,133,033 (2,985,213–13,886,681) 1,117,757,585 (135,152,654–3,090,297,040) 1,152,086,754 (140,957,369–3,199,206,567) 49,641,464 (4,448,113–184,293,392) 27,189,678 (5,092,095–122,746,200) 1,142,339,897 (135,772,698–3,193,690,438) 1,219,171,039 (145,312,906–3,500,730,030) 64,933,829 (230,230–443,199,567) 2,422,849 (1,913,953–3,163,977) 29,345,060 (748,428–122,473,626) 96,701,738 (2,892,611–568,837,170) 59,208,118 (1,495,230–292,758,796) 336,660 (261,069–450,823) 408,850,781 (182,277,670–784,700,391) 468,395,559 (184,033,969–1,077,910,010) 124,141,947 (1,725,460–735,958,363) 2,759,509 (2,175,022–3,614,800) 438,195,841 (183,026,098–907,174,017) 565,097,297 (186,926,580–1,646,747,180) 76,824,603 (270,812–535,645,493) 2,866,524 (2,244,369–3,745,141) 34,718,769 (874,114–146,916,188) 114,409,896 (3,389,295–686,306,822) 51,079,570 (1,304,262–259,015,572) 290,441 (231,959–377,644) 434,529,797 (203,394,956–769,035,553) 485,899,808 (204,931,177–1,028,428,769) 127,904,173 (1,575,074–794,661,065) 3,156,965 (2,476,328–4,122,785) 469,248,566 (204,269,070–915,951,741) 600,309,704 (208,320,472–1,714,735,591) 66,106,756 (5,049,619–257,791,170) 26,353,082 (2,772,695–142,331,647) 32,299,504 (818,254–135,243,017) 124,759,342 (8,640,568–535,365,834) 92,170,296 (1,851,184–499,751,392) 24,797,566 (12,682,995–44,310,416) 257,819,252 (161,389,949–386,916,117) 374,787,114 (175,924,128–930,977,925) 158,277,052 (6,900,803–757,542,562) 51,150,648 (15,455,690–186,642,063) 290,118,756 (162,208,203–522,159,134) 499,546,456 (184,564,696–1,466,343,759) 59,953,488 (4,571,395–234,173,487) 23,900,117 (2,495,003–129,099,485) 29,293,041 (738,199–123,012,657) 113,146,646 (7,804,597–486,285,629) 106,006,168 (2,123,242–578,441,508) 28,519,979 (14,590,286–50,751,625) 27,999,828 (14,338,511–49,482,251) 162,525,975 (31,052,039–678,675,384) 165,959,656 (6,694,637–812,614,995) 52,420,096 (17,085,289–179,851,110) 57,292,869 (15,076,710–172,494,908) 275,672,621 (38,856,636–1,164,961,013) 23,926,864 (1,829,213–93,543,978) 9,538,308 (1,009,249–51,469,988) 11,690,573 (293,670–48,937,108) 45,155,745 (3,132,132–193,951,074) 38,871,071 (784,162–211,014,366) 10,457,902 (5,341,398–18,682,562) 10,267,170 (5,278,930–18,143,636) 59,596,143 (11,404,490–247,840,564) 62,797,935 (2,613,375–304,558,344) 19,996,210 (6,350,647–70,152,550) 21,957,743 (5,572,600–67,080,744) 104,751,888 (14,536,622–441,791,638) Note: Values are expressed in Thai Baht (mean with 95% Crl). Estimate Cost Per Case Across Different Age Groups DMCs of RSV‐associated ILI range from 2149 THB (61 USD) for the 2–4 years age group to 6650 THB (190 USD) for the 18–49 and 50–64 years age groups. For RSV‐associated SARI, the DMCs range from 15,430 THB (441 USD) in the 2–4 years age group to 50,569 THB (1446 USD) in older age groups (65–74, 75–84, and ≥ 85 years). Direct non‐medical costs for RSV‐associated ILI and SARI were lowest in the 18–49 and 50–64 years age groups at 248 THB (7 USD), whereas the highest costs were 2452 THB (70 USD) for ILI in multiple age groups and 13,605 THB (389 USD) for SARI in older age groups. Indirect costs for RSV‐associated ILI were uniformly low across most age groups at 3005 THB (85 USD), but for SARI, the costs ranged from 4674 THB (133 USD) in the 2–4 years age group to 13,357 THB (382 USD) in older age groups. Premature death costs due to RSV‐associated SARI were highest in the < 1‐year age group at 7,240,866 THB (207,118 USD) and lowest in the older age groups at 1,326,041 THB (37,930 USD) The estimated cost per case for other age groups can be found in Appendix 10. Estimate the Economic Burden by Integrating Data From ILI Patients Seeking Care Across Various Healthcare Settings The total economic burden of RSV escalated from 6.2 billion THB (177 million USD) to 8.4 billion THB (239 million USD) when considering patients seeking care in various settings, including community health centers (937 million THB; 27 million USD), pharmacies (554 million THB; 16 million USD), private clinics (322 million THB; 9.2 million USD), and private hospitals (18 million THB; 0.5 million USD). Patients who did not seek care still contributed 326 million THB (9.3 million USD), primarily due to indirect costs (Appendix 11). Across settings, the < 1 year age group consistently had the highest costs, including 232 million THB (6.6 million USD) at community health centers, 134 million THB (3.8 million USD) at pharmacies, and 79 million THB (2.2 million USD) at private clinics. In contrast, the ≥ 85 years group incurred the lowest costs, ranging from 2.5 million THB (0.07 million USD) at private hospitals to 31 million THB (0.88 million USD) at community health centers (Appendix 12). The figure representing the cost distribution across age groups and settings can be found in Appendix 13. Discussion To the best of our knowledge, our study provides a comprehensive national estimate of the disease and economic burden of RSV in Thailand. Our findings highlight that the highest estimated cases of RSV infection were observed in children under 1 year of age, whereas the lowest estimated cases were found in the age group over 85 years. These findings are consistent with previous studies, which found that children under 1 year of age have more cases than older adults [33]. Moreover, deaths from RSV‐associated SARI were found to be highest among older adults, especially those aged 75–84 years. This finding is in concordance with previous studies that reported higher mortality rates in older adults compared to children [34]. The incidence of RSV in Thailand is particularly high among infants and young children, aligning closely with rates reported in countries like Egypt [35], Vietnam [36], and Hong Kong [37]. This highlights a shared vulnerability in early childhood across middle‐ and high‐income nations. Although RSV incidence declines significantly in older children and adults, Thailand follows a similar pattern seen globally, with relatively low rates in healthy adults and a sharp increase again in the older adult population [38]. Compared to Western countries like the USA [39, 40], Canada [41], and Germany [42], Thailand's RSV‐associated hospitalization rates among older adults are comparable, though sometimes slightly lower, which should be interpreted with caution given several factors that limit direct cross‐country comparison. Differences in reported incidence and hospitalization rates may reflect variation in diagnostic sensitivity and testing thresholds, the breadth and intensity of surveillance coverage, differences in healthcare access and care‐seeking behavior, local thresholds and practices for hospital admission, the extent of population aging, and heterogeneous case definitions for RSV‐associated ILI and SARI. Consequently, the comparable or slightly lower rates observed in Thailand may partly reflect these methodological and health‐system differences rather than a genuinely lower underlying disease burden. The economic burden of RSV infections in Thailand represented about 0.03% of the national GDP in 2023. In comparison, the economic burden of influenza ranged from 31.1 to 83.6 million USD annually, equivalent to 0.01%–0.02% of the national GDP, based on values adjusted to 2018 [43, 44]. The total economic burden of RSV appears to be substantially higher, approximately three to eight times greater than that of influenza. This comparison should be interpreted with caution: the RSV and influenza estimates were generated using different modeling approaches, included different cost components, and were based on different costing years and inflation, discounting, and productivity‐valuation assumptions. The apparent difference in magnitude may partly reflect methodological heterogeneity rather than a true difference in underlying burden. Additionally, whereas lost productivity accounted for approximately 50%–53% of influenza‐related costs, the economic burden of RSV was primarily driven by costs associated with premature deaths from RSV‐associated SARI (69.35%). Indeed, indirect costs accounted for roughly 78% of the total economic burden (138 of 177 million USD), the overwhelming majority of which arose from productivity losses attributed to mortality among hospitalized patients rather than from direct medical expenditure. This concentration warrants cautious interpretation, because mortality‐related costs were valued using a human‐capital approach in which the productivity lost from deaths occurring before the average Thai life expectancy (75.3 years) is highly sensitive to the discount rate, the monetary value assigned to lost productivity, and the life‐expectancy threshold used to define death. Under alternative economic assumptions, for example a friction‐cost approach or a different discount rate, the dominant share attributed to death could change substantially, so this finding should be read as a function of the chosen valuation framework rather than a fixed feature of the burden. Preventing premature deaths through strategies like immunization and early treatment may reduce the economic burden of RSV‐associated SARI. Overall, these findings indicate that RSV imposes a considerable economic burden on Thailand's healthcare system and economy; however, a direct head‐to‐head ranking against influenza is limited by these methodological differences and would need to be confirmed using harmonized methods. The economic burden of RSV varied across different age groups, with the highest total burden in infants < 1 year and the lowest in those aged ≥ 85 years. These patterns are explained by the societal‐perspective, human‐capital valuation of mortality, which dominated the total economic burden (indirect costs comprising around 78%, largely productivity losses from RSV‐associated SARI deaths). The low total in those aged ≥ 85 years reflects the smallest number of cases together with minimal attributable productivity loss, because deaths above the average Thai life expectancy (75.3 years) forgo essentially no remaining productive years. Conversely, the high total in infants < 1 year reflects the largest number of cases combined with the highest death cost per case, as each infant death forgoes approximately 75 discounted productive years. Notably, although infants < 1 year had the lowest direct medical cost per case because infant RSV episodes are less resource‐intensive and shorter than the severe SARI hospitalizations of older adults, they contributed the highest total direct medical cost, reflecting case volume rather than per‐case intensity. RSV‐associated ILI carried a lower economic burden than RSV‐associated SARI across all age groups because SARI and its associated mortality concentrate at the extremes of age, the trends observed for SARI‐ and ILI‐associated RSV diverge across age groups. Moreover, the second and third highest direct medical and non‐medical costs were found in the 75–84 and 65–74 age groups, respectively. These findings emphasize the significant disease and economic burden in both infants and older adults, highlighting the need for preventive strategies to mitigate the impact on these vulnerable populations. These results align with previous studies on influenza, which also found that both young children and older adults with comorbidities bear a substantial burden from respiratory infection [43]. The economic burden of RSV is also substantial in other Southeast Asian countries. In Vietnam, RSV‐associated ALRI in children under 2 years of age incurs a median cost per episode of 52 USD for outpatients and 165 USD for inpatients [45]. Indirect costs—particularly lost income—further intensify the financial strain, with total out‐of‐pocket spending reaching up to 70% of the monthly minimum wage for a single hospital admission [45]. In Singapore, the total annual cost of RSV infection in children under 6 months was estimated at 4.7 million USD [46]. Although these studies provide important insights, most focus on limited age groups, leaving significant gaps in knowledge about the broader economic burden of RSV across different age groups—especially in Southeast Asia. The details comparing the findings of the current study with other studies can be found in Appendix 14. To date, comprehensive estimates that span multiple age groups remain scarce in the region. Our study in Thailand demonstrates a practical modeling approach to estimate the full economic burden of RSV, accounting for DMCs, direct non‐medical costs, and indirect costs across different age groups. This model could be replicated or adapted in other countries to reflect local epidemiology, healthcare systems, and cost structures. Encouraging such studies will enable policymakers to better understand their own national burden of RSV, tailor prevention strategies, and allocate resources more effectively. The findings of this study have several important implications for public health policy in Thailand. First, expanding RSV surveillance systems to better capture community‐level infections—beyond hospital‐based settings—is essential for producing more accurate national burden estimates. Given the high number of RSV‐related hospitalizations and deaths, particularly among infants and older adults, the introduction of cost‐effective preventive measures—such as maternal RSV vaccination (e.g., bivalent PreF vaccine; Abrysvo), long‐acting monoclonal antibodies for infants (e.g., Nirsevimab and Clesrovimab), and RSV vaccines for older adults (e.g., adjuvanted monovalent RSV vaccine; Arexvy and Abrysvo)—warrant formal evaluation for inclusion in national immunization strategies, contingent on local cost‐effectiveness evidence; the present study estimates disease and economic burden and does not establish that any specific intervention represents value for money in the Thai context. These treatments have been introduced in Thailand, but there are limitations, as they are not reimbursed under Thailand's Universal Coverage Scheme (UCS)—despite many studies from other countries suggesting that these strategies are cost‐effective [47, 48, 49, 50]. Future research should focus on cost‐effectiveness studies of preventive treatments, long‐term follow‐up of RSV cases, assessment of quality of life, and tracking of post‐hospitalization complications to fully capture the broader health and economic impact of RSV and to inform more comprehensive prevention and management strategies. Strengths and Limitations This study presents the first national‐level assessment of both the disease and economic burden of RSV in Thailand, using an incidence‐based approach from a societal perspective over 1 year. A key strength of the study lies in its comprehensive use of data collected from multiple surveillance sites across the country, allowing for robust disease burden estimates. The integration of micro‐costing and a bottom‐up method, in line with HITAP guidelines, ensures detailed and accurate cost estimation. Moreover, the study employed scenario analysis and probabilistic sensitivity analysis to validate the robustness of its findings, further enhancing credibility. Another strength is the incorporation of healthcare‐seeking behavior, which provided a more realistic estimation of the burden beyond hospital settings. However, the study has several limitations. First, because the analysis relied on hospital‐based surveillance, the true incidence of community‐acquired RSV remains uncertain and the overall burden may be underestimated. This underestimation is likely uneven across age groups: RSV detection depends on viral load and shedding duration, which are generally higher and more prolonged in young children than in adults and older adults, so under‐detection—and consequently underestimation of burden—is likely greater in the latter groups. Age‐specific estimates were further limited by the unavailability of granular age‐specific RSV incidence data for Thailand; the age distribution of cases was instead derived by calibrating US MarketScan commercial‐claims weights to Thai surveillance totals. The underlying age‐specific pattern of RSV disease occurrence is not expected to differ substantially across countries, as it is driven primarily by age‐related immunological susceptibility rather than setting‐specific factors. Nonetheless, the calibration approach may still have introduced inaccuracies given the marked differences in healthcare‐seeking behavior, testing practices, insurance coverage, and population age structure between the two settings, which could affect the precision of the derived Thai age‐specific estimates. Estimates also could not be disaggregated for infants under 6 months, as underlying data were available only for broader age bands, so burden in this subgroup may likewise be underestimated. Second, generalizability is limited by the fact that estimates reflect RSV activity during a single year (2023) and were derived only from sentinel surveillance sites that do not constitute a nationally representative sample; generalizability is further limited by between‐season variability in RSV circulation and by the lingering effects of the COVID‐19 pandemic, which suppressed circulation during 2020–2021 and was followed by atypical, out‐of‐season resurgences, such that the 2023 estimates may not be comparable with pre‐pandemic years, underscoring the need for ongoing multi‐year surveillance. The reliance on calendar‐year aggregated data also precluded burden estimates for specific peak respiratory‐virus seasons. Third, estimates were not adjusted for co‐circulation of other respiratory viruses or co‐infection; episodes in which RSV was detected were attributed to RSV, potentially overstating RSV‐specific costs. The analysis also did not capture RSV‐related exacerbations of chronic conditions beyond the recorded ILI and SARI episodes, nor certain indirect costs—such as those from long‐term complications and caregiver productivity loss beyond hospitalization—which were not fully captured. Finally, because surveillance and costing data were aggregated rather than individual‐level, estimates were not stratified by risk profile (e.g., comorbidities or socioeconomic status) and instead represent population averages; the true burden among the highest‐risk individuals is therefore likely higher than reported. Conclusions RSV not only poses a substantial health risk but also places a notable economic burden on Thailand's economy and healthcare system, particularly through costs related to direct medical expenses and premature deaths. These findings underscore the urgent need for targeted prevention strategies and expanded surveillance to better inform policy and protect vulnerable populations. Author Contributions Kansak Boonpattharatthiti: data curation, validation, formal analysis, writing – original draft, writing – review and editing, methodology. Chonnamet Techasaensiri: conceptualization, writing – review and editing. Wanatpreeya Phongsamart: conceptualization, writing – review and editing. Pilailuk Akkapaiboon Okada: data curation. Chanthawat Patikorn: conceptualization, writing – review and editing, methodology, validation, formal analysis. Prabda Praphasiri: data curation. Teerapon Dhippayom: conceptualization, methodology, supervision, writing – review and editing, visualization, validation. Nathorn Chaiyakunapruk: conceptualization, methodology, supervision, writing – review and editing, funding acquisition, project administration, visualization. Funding This work was supported by a grant from Pediatric Infectious Disease Society of Thailand. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Appendix S1: Estimated RSV cases for each surveillance sites. Appendix S2: Adjusting the RSV incidence from USA to Thailand. Appendix S3: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI, for entire country. Appendix S4: Estimating the number of premature deaths among RSV‐associated SARI patients. Appendix S5: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI for Bangkok. Appendix S6: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI for non‐Bangkok provinces. Appendix S7: Estimating the number of RSV‐associated ILI patients seeking care in other settings. Appendix S8: Calculation of the cost of premature mortality. Appendix S9: Total Economic Burden of RSV‐Associated Infections Categorized by Cost Components. Appendix S10: Estimated cost per case across different age groups. Appendix S11: Total economic burden of RSV‐associated SARI patients and RSV‐associated ILI patients seeking care across different healthcare settings in Thailand. Appendix S12: Total economic burden of RSV‐associated SARI patients and RSV‐associated ILI patients seeking care across different healthcare settings and age groups in Thailand. Appendix S13: Figure displaying the distribution of the total economic burden among RSV‐associated SARI and ILI patients seeking care, by healthcare setting and age group, in Thailand. Appendix S14: Comparative summary of findings. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. References Associated Data Supplementary Materials Appendix S1: Estimated RSV cases for each surveillance sites. Appendix S2: Adjusting the RSV incidence from USA to Thailand. Appendix S3: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI, for entire country. Appendix S4: Estimating the number of premature deaths among RSV‐associated SARI patients. Appendix S5: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI for Bangkok. Appendix S6: Estimating the number of RSV‐associated ILI and number of RSV‐associated SARI for non‐Bangkok provinces. Appendix S7: Estimating the number of RSV‐associated ILI patients seeking care in other settings. Appendix S8: Calculation of the cost of premature mortality. Appendix S9: Total Economic Burden of RSV‐Associated Infections Categorized by Cost Components. Appendix S10: Estimated cost per case across different age groups. Appendix S11: Total economic burden of RSV‐associated SARI patients and RSV‐associated ILI patients seeking care across different healthcare settings in Thailand. Appendix S12: Total economic burden of RSV‐associated SARI patients and RSV‐associated ILI patients seeking care across different healthcare settings and age groups in Thailand. Appendix S13: Figure displaying the distribution of the total economic burden among RSV‐associated SARI and ILI patients seeking care, by healthcare setting and age group, in Thailand. Appendix S14: Comparative summary of findings. Data Availability Statement The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.